The circadian based hypertension-management: new approach for better blood pressure goals
DOI:
https://doi.org/10.21776/ub.hsj.2024.005.04.2Keywords:
Circardian Rhytm, Blood Pressure, Ambulatory Blood Pressure MonitoringAbstract
Hypertension, a primary changeable risk factor for overall mortality, affects approximately 1.4 billion people worldwide, accounting for about 31% of the global adult population. The primary method of diagnosis is through in-office or clinic blood pressure readings, which do not consider the circadian rhythm’s fluctuations. Various homeostatic parameters, including blood pressure, are influenced by circadian rhythms, which follow a day-night cycle. Blood pressure typically decreases at night and rises during the day in line with the circadian rhythm. 24-hour ambulatory blood pressure monitoring offers a more comprehensive evaluation of hypertension. The phenomena of nocturnal blood pressure and the dipping pattern are closely interconnected characteristics that provide comparable therapeutic insights. In hypertensive patients, nighttime blood pressures were found to be a better predictor of cardiovascular and all-cause mortality outcomes than daytime systolic pressures. The current range of anti-hypertensive medications used to manage hypertension reveals that while some have an impact on circadian rhythms, others do not. Existing research on these drugs presents mixed views on the benefits of administering hypertension medication in the morning versus the evening. A significant study, known as the BedMed trial, is currently in progress to assess the cardiovascular effects of administering hypertension medication at bedtime as opposed to the traditional morning administration. This study could potentially provide valuable insights for improved future management of hypertension.
References
Costello HM, Gumz ML. Circadian Rhythm, Clock Genes, and Hypertension: Recent Advances in Hypertension. Hypertension. 2021;78(5):1185-1196. doi:10.1161/HYPERTENSIONAHA.121.14519
Smolensky MH, Hermida RC, Geng YJ. Chronotherapy of cardiac and vascular disease: timing medications to circadian rhythms to optimize treatment effects and outcomes. Curr Opin Pharmacol. 2021;57:41-48. doi:10.1016/j.coph.2020.10.014
Hermida RC, Hermida-Ayala RG, Smolensky MH, Mojón A, Fernández JR. Ingestion-time differences in the pharmacodynamics of hypertension medications: Systematic review of human chronopharmacology trials. Adv Drug Deliv Rev. 2021;170:200-213. doi:10.1016/j.addr.2021.01.013
Rabinovich-Nikitin I, Lieberman B, Martino TA, Kirshenbaum LA. Circadian-Regulated Cell Death in Cardiovascular Diseases. Circulation. 2019;139(7):965-980. doi:10.1161/CIRCULATIONAHA.118.036550
Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. Circadian rhythms and cardiovascular health. Sleep Med Rev. 2012;16(2):151-166. doi:10.1016/j.smrv.2011.04.003
Thoonkuzhy C, Rahman M. New Insights on Chronotherapy in Hypertension: Is Timing Everything? Curr Hypertens Rep. 2020;22(4). doi:10.1007/s11906-020-1032-x
Kario K, Hoshide S, Chia YC, et al. Guidance on ambulatory blood pressure monitoring: A statement from the HOPE Asia Network. J Clin Hypertens. 2021;23(3):411-421. doi:10.1111/jch.14128
Kario K, Hoshide S, Chia YC, et al. Guidance on ambulatory blood pressure monitoring: A statement from the HOPE Asia Network. J Clin Hypertens. 2021;23(3):411-421. doi:10.1111/jch.14128
Huang QF, Yang WY, Asayama K, et al. Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension. Hypertension. 2021;77(2):254-264. doi:10.1161/HYPERTENSIONAHA.120.14591
Ziegler MG, Milic M. Sympathetic nerves and hypertension in stress, sleep apnea, and caregiving. Curr Opin Nephrol Hypertens. 2017;26(1):26-30. doi:10.1097/MNH.0000000000000288
O’Brien E, Parati G, Stergiou G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731-1768. doi:10.1097/HJH.0b013e328363e964
Sogunuru GP, Kario K, Shin J, et al. Morning surge in blood pressure and blood pressure variability in Asia: Evidence and statement from the HOPE Asia Network. J Clin Hypertens. 2019;21(2):324-334. doi:10.1111/jch.13451
Burnier M, Kreutz R, Narkiewicz K, Kjeldsen S, Oparil S, Mancia G. Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: Is dosing in the evening better than in the morning? J Hypertens. 2020;38(8):1396-1406. doi:10.1097/HJH.0000000000002532
Kumar B, Chawla O, Bhattacharjee M, Singh A. Circadian rhythm of blood pressure: Implications for antihypertensive management. Indian Journal of Medical Specialities. 2021;12(2):53. doi:10.4103/injms.injms_4_21
De Giorgi A, Mallozzi Menegatti A, Fabbian F, Portaluppi F, Manfredini R. Circadian rhythms and medical diseases: Does it matter when drugs are taken? Eur J Intern Med. 2013;24(8):698-706. doi:10.1016/j.ejim.2013.03.019
Mathur P, Kadavath S, Marsh JD, Mehta JL. Chronotherapy for hypertension: Improvement in patient outcomes with bedtime administration of antihypertensive drugs. Eur Heart J. 2020;41(48):4577-4579. doi:10.1093/eurheartj/ehz836
Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. The Lancet. 2022;400(10361):1417-1425. doi:10.1016/S0140-6736(22)01786-X
Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol Int. 2010;27(8):1629-1651. doi:10.3109/07420528.2010.510230
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913. doi:10.1016/S0140-6736(02)11911-8
Garrison SR, Kolber MR, Allan GM, et al. Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial. BMJ Open. 2022;12(2). doi:10.1136/bmjopen-2021-059711
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).